Abstract | BACKGROUND: AIM: To report the safety and efficacy outcomes of long-term, CZP therapy from PRECiSE 3, in which patients received treatment up to 7 years treatment. METHODS: Patients completing PRECiSE 1 or 2 were eligible to enter PRECiSE 3 in which they received CZP 400 mg, open-label, every 4 weeks (without additional induction therapy) for up to 7 years, for up to 91 doses from study start. Safety (adverse events, including infections and malignancies) and efficacy (Harvey-Bradshaw Index, faecal calprotectin, C-reactive protein) were prospectively monitored. Remission was analysed using observed cases, last observation carried forward imputation and nonresponder imputation. RESULTS: A total of 595 patients entered the study; 117 (20%) completed 7 years. Discontinuation rates were 29.2%, 13.6%, 16.1%, 7.9%, 5.0%, 4.5% and 3.9% (years 1-7 respectively). During 1920 patient-years of exposure to CZP, no new safety signals were observed. Incidence rates (new cases/100 patient-years) for serious infections and malignant neoplasms were 4.37 and 1.06 respectively. No lymphoproliferative malignancies were reported. Clinical remission rates were ≥68% at each year (observed cases); rates by last observation carried forward and nonresponder imputation were 58% and 45% at year 1, 56% and 26% at year 3 and 55% and 13% at year 7 respectively. CONCLUSION:
Certolizumab pegol was well tolerated in the long-term treatment of Crohn's disease, with sustained remission in some patients continuing in the study for up to 7 years. ClinicalTrials.gov identifier NCT00552058.
|
Authors | W J Sandborn, S D Lee, C Randall, A Gutierrez, D A Schwartz, S Ambarkhane, C Kayhan, B Pierre-Louis, S Schreiber, G R Lichtenstein |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 40
Issue 8
Pg. 903-16
(Oct 2014)
ISSN: 1365-2036 [Electronic] England |
PMID | 25146586
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Immunoglobulin Fab Fragments
- Immunosuppressive Agents
- Leukocyte L1 Antigen Complex
- Polyethylene Glycols
- C-Reactive Protein
- Certolizumab Pegol
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- C-Reactive Protein
(metabolism)
- Certolizumab Pegol
- Crohn Disease
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Immunoglobulin Fab Fragments
(adverse effects, therapeutic use)
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Leukocyte L1 Antigen Complex
(metabolism)
- Male
- Middle Aged
- Polyethylene Glycols
(adverse effects, therapeutic use)
- Remission Induction
- Treatment Outcome
|